Korean Journal of Radiology

The Korean Society of Radiology (대한영상의학회)
권호 표지
DOI QR코드

DOI QR Code

2022 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for Transarterial Therapy of Hepatocellular Carcinoma: What's New?

  • In Joon Lee (Department of Radiology, National Cancer Center) ;
  • Ho Jong Chun (Department of Radiology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea) ;
  • Jin Wook Chung (Department of Radiology, Seoul National University Hospital, Seoul National University College of Medicine)
  • Received : 2022.07.24
  • Accepted : 2022.09.13
  • Published : 2023.01.01
Download PDF
⟨ Previous Next ⟩

Abstract

Keywords

References

  1. Korean Liver Cancer Association (KLCA), National Cancer Center (NCC) Korea. 2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma. Korean J Radiol 2022;23:1126-1240 https://doi.org/10.3348/kjr.2022.0822
  2. Lammer J, Malagari K, Vogl T, Pilleul F, Denys A, Watkinson A, et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 2010;33:41-52 https://doi.org/10.1007/s00270-009-9711-7
  3. Sacco R, Bargellini I, Bertini M, Bozzi E, Romano A, Petruzzi P, et al. Conventional versus doxorubicin-eluting bead transarterial chemoembolization for hepatocellular carcinoma. J Vasc Interv Radiol 2011;22:1545-1552 https://doi.org/10.1016/j.jvir.2011.07.002
  4. Golfieri R, Giampalma E, Renzulli M, Cioni R, Bargellini I, Bartolozzi C, et al. Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma. Br J Cancer 2014;111:255-264 https://doi.org/10.1038/bjc.2014.199
  5. Reig M, Forner A, Rimola J, Ferrer-Fabrega J, Burrel M, Garcia-Criado A, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol 2022;76:681-693 https://doi.org/10.1016/j.jhep.2021.11.018
  6. Monier A, Guiu B, Duran R, Aho S, Bize P, Deltenre P, et al. Liver and biliary damages following transarterial chemoembolization of hepatocellular carcinoma: comparison between drug-eluting beads and lipiodol emulsion. Eur Radiol 2017;27:1431-1439 https://doi.org/10.1007/s00330-016-4488-y
  7. Lee M, Chung JW, Lee KH, Won JY, Chun HJ, Lee HC, et al. Korean multicenter registry of transcatheter arterial chemoembolization with drug-eluting embolic agents for nodular hepatocellular carcinomas: six-month outcome analysis. J Vasc Interv Radiol 2017;28:502-512 https://doi.org/10.1016/j.jvir.2016.08.017
  8. Lee M, Chung JW, Lee KH, Won JY, Chun HJ, Lee HC, et al. Prospective multi-center Korean registry of transcatheter arterial chemoembolization with drug-eluting embolics for nodular hepatocellular carcinoma: a two-year outcome analysis. Korean J Radiol 2021;22:1658-1670 https://doi.org/10.3348/kjr.2020.1117
  9. Lee IJ, Lee JH, Lee YB, Kim YJ, Yoon JH, Yin YH, et al. Effectiveness of drug-eluting bead transarterial chemoembolization versus conventional transarterial chemoembolization for small hepatocellular carcinoma in Child-Pugh class A patients. Ther Adv Med Oncol 2019;11:1758835919866072
  10. Kim HC, Kim YJ, Lee JH, Suh KS, Chung JW. Feasibility of boosted radioembolization for hepatocellular carcinoma larger than 5 cm. J Vasc Interv Radiol 2019;30:1-8 https://doi.org/10.1016/j.jvir.2018.07.002
  11. Garin E, Tselikas L, Guiu B, Chalaye J, Edeline J, de Baere T, et al. Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial. Lancet Gastroenterol Hepatol 2021;6:17-29 https://doi.org/10.1016/S2468-1253(20)30290-9
  12. Salem R, Johnson GE, Kim E, Riaz A, Bishay V, Boucher E, et al. Yttrium-90 radioembolization for the treatment of solitary, unresectable HCC: the LEGACY study. Hepatology 2021;74:2342-2352 https://doi.org/10.1002/hep.31819
  13. Kim E, Sher A, Abboud G, Schwartz M, Facciuto M, Tabrizian P, et al. Radiation segmentectomy for curative intent of unresectable very early to early stage hepatocellular carcinoma (RASER): a single-centre, single-arm study. Lancet Gastroenterol Hepatol 2022;7:843-850 https://doi.org/10.1016/S2468-1253(22)00091-7
  14. Currie BM, Hoteit MA, Ben-Josef E, Nadolski GJ, Soulen MC. Radioembolization-induced chronic hepatotoxicity: a single-center cohort analysis. J Vasc Interv Radiol 2019;30:1915-1923 https://doi.org/10.1016/j.jvir.2019.06.003
  15. Kuo TM, Chang KM, Kao KJ. Why cannot BCLC 0- or A-stage patients receive curative treatment? Gastrointest Tumors 2020;7:125-133 https://doi.org/10.1159/000509824
  16. Oh JH, Sinn DH, Choi GS, Kim JM, Joh JW, Kang TW, et al. Comparison of outcome between liver resection, radiofrequency ablation, and transarterial therapy for multiple small hepatocellular carcinoma within the Milan criteria. Ann Surg Treat Res 2020;99:238-246 https://doi.org/10.4174/astr.2020.99.4.238
  17. Yang HJ, Lee JH, Lee DH, Yu SJ, Kim YJ, Yoon JH, et al. Small single-nodule hepatocellular carcinoma: comparison of transarterial chemoembolization, radiofrequency ablation, and hepatic resection by using inverse probability weighting. Radiology 2014;271:909-918 https://doi.org/10.1148/radiol.13131760
  18. Yun BY, Lee HW, Min IK, Kim SU, Park JY, Kim DY, et al. Prognosis of early-stage hepatocellular carcinoma: comparison between trans-arterial chemoembolization and radiofrequency ablation. Cancers (Basel) 2020;12:2527
  19. Sinn DH, Lee HW, Paik YH, Kim DY, Kim YJ, Kim KM, et al. Patterns and outcomes in hepatocellular carcinoma patients with portal vein invasion: a multicenter prospective cohort study. Dig Dis Sci 2021;66:315-324 https://doi.org/10.1007/s10620-020-06134-4
  20. Yoon SM, Ryoo BY, Lee SJ, Kim JH, Shin JH, An JH, et al. Efficacy and safety of transarterial chemoembolization plus external beam radiotherapy vs sorafenib in hepatocellular carcinoma with macroscopic vascular invasion: a randomized clinical trial. JAMA Oncol 2018;4:661-669 https://doi.org/10.1001/jamaoncol.2017.5847